HD-OPM Archive
Topics › GLP-1 drugs (semaglutide, tirzepatide)

Tirzepatide shrank breast tumors in obese mice, tracking body and liver fat loss

Louis Nervegna · Dec 07, 2025 · ♥ 8 reactions · 2 comments · original Facebook post
GLP-1 drugs (semaglutide, tirzepatide)CancerWeight, visceral & liver fat
AI summary & key facts

Louis shares an ENDO 2025 mouse study in which tirzepatide reduced body fat by about 20% and gave significantly smaller breast tumors in obese mice, with tumor size correlating with body fat, liver fat and weight. He compares it to calorie restriction slowing tumors; the findings are preliminary and animal-based.

Calorie restriction has long been known to slow cancer growth in mice. These new GLP-1 agonist drugs work by the same mechanism.

Links to other write-ups on this study:

scitechdaily.comWeight-Loss Drug Mounjaro Shrinks Breast Cancer Tumors in Micescitechdaily.com ScienceDailyWeight-loss wonder drug Mounjaro/Zepbound shrinks breast cancer tumorsA cutting-edge mouse study reveals that tirzepatide, the dual GLP-1/GIP drug already hailed for impressive weight loss, does more than trim fat: it slashes the growth of obesity-linked breast tumors. University of Michigan researchers found mice lost about 20 % body weight and adipose tissue while their tumors shrank in tandem, hinting that the blockbuster…sciencedaily.com

#glp1HD #cancerHD #calorierestrictionHD #breastcancerHD #miceHD

Research cited

In a promising new study, the widely used weight-loss drug tirzepatide—known commercially as Mounjaro for diabetes and Zepbound for obesity—has shown a surprising secondary benefit: shrinking breast cancer tumors in obese mice.

Presented at ENDO 2025, the research revealed that mice treated with tirzepatide not only lost about 20% of their body fat but also developed significantly smaller breast tumors compared to untreated controls. The study found that tumor size strongly correlated with overall body fat, liver fat, and total weight, suggesting that reducing obesity might directly impact tumor growth.

Tirzepatide is part of a new class of medications that activate GLP-1 and GIP receptors to curb appetite and regulate blood sugar. While originally developed for metabolic diseases, this dual-action drug may also help reduce cancer risks tied to obesity—especially in breast cancer, where excess fat is a known risk factor.

Though the findings are preliminary and based on animal models, they open new avenues for cancer prevention and treatment strategies—particularly for patients who struggle with weight loss through traditional means. Ongoing research aims to distinguish the drug’s direct effects on tumors from those due solely to fat loss.

Follow Science Sphere for regular scientific updates

Source: Weight-Loss Drug Mounjaro Shrinks Breast Cancer Tumors in Mice (SciTechDaily, Sep 2025)

No photo description available.
← newer: Aspirin blocks platelet TXA2 suppression of T cells and reduolder: COVID, flu and RSV infections can destabilize people with he →